{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"0.720","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"4,124,080,000","primaryexch":"HKEX","ric":"2181.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"K","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BHRH2D9","am":"177.76","iv":"","ew_strike":"","as":"0.730","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"0.710","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"2,000","update_time":"2025-09-26 10:38:37.0","lo52":"0.250","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Jiao Shuge","underlying_ric":"2181.HK","hi52":"0.940","issuer_name":"Mabpharm Ltd. - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 15:58","aum_date":"","lo":"0.710","mkt_cap":"2.96","f_aum_hkd":null,"ew_sub_per_to":"","ls":"0.720","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-0.010","aum":"","issued_shares_class_B":null,"vo":"250.00","secondary_listing_flag":false,"listing_date":"31 May 2019","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Mabpharm Ltd. - B","nm_s":"MABPHARM-B","sym":"2181","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.","op":"0.710","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room A, 18/F<br/>Hong Xiang Centre<br/>83 Queen's Road East<br/>Wanchai, Hong Kong","pc":"-1.37","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"0.730","isin":"KYG5780F1046","moneyness":""}},"qid":"1758890898992"}
